U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

On the face of it, Pfizer's ROE is not much to talk about. A quick further study shows that the company's ROE doesn't compare ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

We recently compiled a list of the 12 Most Reliable Dividend Stocks To Buy According to Hedge Funds. In this article, we are ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...

The metaverse hype is over, but developer Cassette Group has been working with Pfizer to realise its forgotten potential.

The higher you go, the scarier it gets. Many of us are more afraid of falling off an especially tall ladder than a shorter ...